SecurityRARX / Ra Pharmaceuticals, Inc. (74933V108)
Common Shares Outstanding32,340,155 shares (as of 2018-06-30)
Total Insiders32
Total Directors10
Total Officers5

Stock Insider Trading (from SEC Form 4)

Ra Pharmaceuticals, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RARX / Ra Pharmaceuticals, Inc. insiders include Shah Rajeev M., Treco Douglas A, NEW ENTERPRISE ASSOCIATES 13 LP, Farzaneh-Far Ramin, Kolchinsky Peter, Bisgaard Peter, and BASKETT FOREST, Novartis Bioventures Ltd, BARRETT M JAMES, MORGENTHALER VENTURE PARTNERS IX LP, NEA 13 GP, Ltd, RA CAPITAL MANAGEMENT, LLC, Weller Harry R, Read Simon, Morgenthaler Management Partners IX, LLC, SANDELL SCOTT D, Brennan Aoife KERINS PATRICK J, NOVARTIS AG, NEA Partners 13, Limited Partnership, BARRIS PETER J, King John C, KOLLURI KRISHNA KITTU, Lubner David Charles, Novo A/S, Mathers Edward T, PEARSON TIMOTHY R, Heft Robert, Lettmann Jason, Viswanathan Ravi, MOTT DAVID M, RA Capital Healthcare Fund LP, .

Insider Roster

Insider Dir Off 10% Shares Owned
Brennan Aoife Director
X
Heft Robert Director
X
PEARSON TIMOTHY R Director
X
Bisgaard Peter Director
X
Shah Rajeev M. Director, 10% Owner
X X
Mathers Edward T Director
X
Kolchinsky Peter Director, 10% Owner
RA Capital Healthcare Fund LP Director, 10% Owner
RA CAPITAL MANAGEMENT, LLC Director, 10% Owner
X X
King John C Chief Commercial Officer
X
NEA 13 GP, Ltd 10% Owner
Viswanathan Ravi 10% Owner
SANDELL SCOTT D 10% Owner
MOTT DAVID M 10% Owner
KERINS PATRICK J 10% Owner
BASKETT FOREST 10% Owner
BARRIS PETER J 10% Owner
BARRETT M JAMES 10% Owner
NEA Partners 13, Limited Partnership 10% Owner
NEW ENTERPRISE ASSOCIATES 13 LP 10% Owner
X 5,490,073
RA Capital Healthcare Fund LP 10% Owner
RA CAPITAL MANAGEMENT, LLC Director, 10% Owner
Kolchinsky Peter 10% Owner
X 3,851,808
Farzaneh-Far Ramin Chief Medical Officer
X
Read Simon Chief Scientific Officer
X
Lubner David Charles Executive V.P. & CFO
X
Treco Douglas A President and CEO, Director
X X
RA CAPITAL MANAGEMENT, LLC Director
Kolchinsky Peter Director
X
Lettmann Jason Director, 10% Owner
X X
Novartis Bioventures Ltd 10% Owner
NOVARTIS AG 10% Owner
X 2,251,457
NOVARTIS AG 10% Owner
Novartis Bioventures Ltd 10% Owner
X 2,308,577
Novo A/S 10% Owner
X
MORGENTHALER VENTURE PARTNERS IX LP 10% Owner
Morgenthaler Management Partners IX, LLC 10% Owner
X
Weller Harry R 10% Owner
X
Viswanathan Ravi 10% Owner
X
SANDELL SCOTT D 10% Owner
X
MOTT DAVID M 10% Owner
X
KOLLURI KRISHNA KITTU 10% Owner
X
KERINS PATRICK J 10% Owner
X
BASKETT FOREST 10% Owner
X
BARRIS PETER J 10% Owner
X
BARRETT M JAMES 10% Owner
X
NEA Partners 13, Limited Partnership 10% Owner
NEW ENTERPRISE ASSOCIATES 13 LP 10% Owner
NEA 13 GP, Ltd 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-02-16 4 NEW ENTERPRISE ASSOCIATES 13 LP P D 6.00 2,000,000 5,490,073 32,940,438
2018-02-14 4 RA CAPITAL MANAGEMENT, LLC See Note P I 6.00 2,500,000 3,851,808 23,110,848
2018-02-14 4 Shah Rajeev M. P I 6 2,500,000 3,851,808 23,110,848
2017-06-19 4 Novartis Bioventures Ltd S D 22.0182 -3,220 2,251,457 49,573,031
2017-06-16 4 Novartis Bioventures Ltd S D 21.2445 -53,200 2,254,677 47,899,486
2017-06-08 4 Novartis Bioventures Ltd S D 22.00 -700 2,307,877 50,773,294
2017-06-07 4 Novartis Bioventures Ltd S D 22.1073 -4,840 2,308,577 51,036,404
2017-06-06 4 Novartis Bioventures Ltd S D 22.9806 -7,274 2,313,417 53,163,711
2017-06-05 4 Novartis Bioventures Ltd S D 23.1146 -4,780 2,320,691 53,641,844
2017-06-02 4 Novartis Bioventures Ltd S D 23.4714 -14,867 2,325,471 54,582,060
2017-06-01 4 Novartis Bioventures Ltd S D 23.8926 -10,722 2,340,338 55,916,760
2017-05-31 4 Novartis Bioventures Ltd S D 23.9426 -35,539 2,351,060 56,290,489
2017-05-26 4 Novartis Bioventures Ltd S D 25.1448 -5,300 2,386,599 60,010,555
2017-05-25 4 Novartis Bioventures Ltd S D 25.00 -53 2,391,899 59,797,475
2017-05-24 4 Novartis Bioventures Ltd S D 25.0051 -17,451 2,391,952 59,810,999
2017-05-18 4 Novartis Bioventures Ltd S D 25.4977 -9,019 2,409,403 61,434,235
2017-05-17 4 Novartis Bioventures Ltd S D 25.5126 -22,534 2,418,422 61,700,233
2017-05-16 4 Novartis Bioventures Ltd S D 26.3296 -20,081 2,440,956 64,269,395
2017-03-01 4 Novartis Bioventures Ltd S D 20.9126 -7,778 2,461,037 51,466,682
2017-02-28 4 Novartis Bioventures Ltd S D 20.8577 -7,847 2,468,815 51,493,803
2017-02-27 4 Novartis Bioventures Ltd S D 20.9582 -57,844 2,476,662 51,906,378
2017-02-24 4 Novartis Bioventures Ltd S D 20.9336 -5,398 2,534,506 53,056,335
2017-02-23 4 Novartis Bioventures Ltd S D 21.0362 -4,999 2,539,904 53,429,929
2017-02-22 4 Novartis Bioventures Ltd S D 21.8553 -749 2,544,903 55,619,619
2016-10-31 4 Novo A/S P D 13.00 246,154 2,031,562 26,410,306
2016-10-31 4 Novo A/S C D 860,438 1,785,408
2016-10-31 4 Novo A/S C D 924,970 924,970
2016-10-31 4 Novartis Bioventures Ltd P D 13.00 84,615 2,545,652 33,093,476
2016-10-31 4 Novartis Bioventures Ltd C D 486,104 2,461,037
2016-10-31 4 Novartis Bioventures Ltd C D 522,561 1,974,933
2016-10-31 4 Novartis Bioventures Ltd C D 1,389,797 1,452,372
2016-10-31 4 Novartis Bioventures Ltd S D 13.00 -339 62,575 813,475
2016-10-31 4 Novartis Bioventures Ltd X D 0.07 62,914 62,914
2016-10-31 4 RA CAPITAL MANAGEMENT, LLC P I 13.00 161,538 1,351,808 17,573,504
2016-10-31 4 RA CAPITAL MANAGEMENT, LLC See footnotes C I 573,624 1,190,270
2016-10-31 4 RA CAPITAL MANAGEMENT, LLC See footnotes C I 616,646 616,646
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP P D 13.00 338,462 3,490,073 45,370,949
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP C D 623,210 3,151,611
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP C D 669,951 2,528,401
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP C D 1,778,227 1,858,450
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP S D 13.00 -435 80,223 1,042,899
2016-10-31 4 NEW ENTERPRISE ASSOCIATES 13 LP X D 0.07 80,658 80,658
2016-10-31 4 BARRETT M JAMES See Note 2 P I 13.00 338,462 3,490,073 45,370,949
2016-10-31 4 BARRETT M JAMES See Note 2 C I 623,210 3,151,611
2016-10-31 4 BARRETT M JAMES See Note 2 C I 669,951 2,528,401
2016-10-31 4 BARRETT M JAMES See Note 2 C I 1,778,227 1,858,450
2016-10-31 4 BARRETT M JAMES See Note 2 S I 13.00 -435 80,223 1,042,899
2016-10-31 4 BARRETT M JAMES See Note 2 X I 0.07 80,658 80,658
2016-10-31 4 BARRIS PETER J See Note 2 P I 13.00 338,462 3,490,073 45,370,949
2016-10-31 4 BARRIS PETER J See Note 2 C I 623,210 3,151,611
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Recent IPO Replimune: Oncolytic Viral Technology

2018-08-28 seekingalpha
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M. (30-0)

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

2018-07-30 seekingalpha
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)

Insiders Are Bullish On Tiny Tonix (Again)

2018-07-24 seekingalpha
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-5)

Riding Ra Pharmaceuticals

2018-07-23 seekingalpha
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)

6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-17)

Top Analyst Upgrades and Downgrades: AEP, Facebook, Microsoft, PayPal, Philip Morris, Spotify, Under Armour and More

2018-07-20 247wallst
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond. (49-2)

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

2018-05-31 seekingalpha
This article is the second of two parts discussing Alexion Pharmaceuticals (ALXN) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXN’s competition. I have previously reviewed a large number of ALXN’s competitors back in October, 2017, but there have been some important developments since worth reviewing. Further, given the recent phase 3 success of ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), and with results in atypical hemolytic uremic syndrome (aHUS) coming in Q4’18, it now becomes prudent to compare the competitors' drugs to ALXN1210, not just Soliris. (146-2)

5 Clinical-Stage Biotech Stocks to Buy Under $10

2018-05-29 investorplace
Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. Conversely, one mishap can send shares crashing. (220-5)

ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech

2018-05-07 seekingalpha
After getting my toes wet in the renal-disease space with my previous overview article, I came across two companies I really like: Achillion (ACHN) and ChemoCentryx (CCXI). Ra Pharmaceuticals (RARX) and Omeros (OMER) are both contenders with potentially great upside as well, and should be followed closely. (27-2)

Alexion Clears A Path For 2nd Generation PNH Drug

2018-04-30 seekingalpha
Alexion obtains positive phase 3 results for SWITCH study in treating patients with rare blood disease. (58-0)